Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
AI compound screen finds new antibiotics against drug-resistant gonorrhea

AI compound screen finds new antibiotics against drug-resistant gonorrhea

New Capabilities

A machine-learning model scanned millions of molecules and surfaced two that kill a pathogen running out of treatments

June 29th, 2026: MP20 and A1 detailed in journal and Nature coverage

Overview

Updated Jun 30

Gonorrhea has shrugged off nearly every drug thrown at it. Now a machine-learning model has scanned about 6 million chemical structures and pulled out two compounds that kill the bacterium in ways existing antibiotics do not.

The work, led by James Collins at Harvard's Wyss Institute with MIT and the Broad Institute, was published in Science Translational Medicine. The lead compound killed the bacterium in a chip lined with living human cells. Both compounds are years from a pharmacy shelf, but they give doctors a new line of attack on a pathogen the World Health Organization lists as a high-priority resistance threat.

Why it matters

Gonorrhea beats every drug class eventually; the AI compounds add two new mechanisms before the current options start failing.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Play on this story Voices Debate Predict Higher or Lower Timeline Connections

Key Indicators

~6 million
Compounds screened
The model virtually evaluated roughly 6 million chemical structures for activity against the bacterium.
83
Confirmed active candidates
Compounds the screen flagged that lab tests confirmed could kill Neisseria gonorrhoeae.
2
Novel-mechanism leads
MP20 and A1 attack the bacterium through routes unlike current antibiotics.
5%
Ceftriaxone resistance, 2024
Resistance to the main first-line drug rose from 0.8% in 2022 to about 5% in 2024, per WHO surveillance.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 3 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

James Collins
James Collins
Bioengineer and lead researcher
Leading the AI antibiotic discovery effort

Organizations Involved

Wyss Institute for Biologically Inspired Engineering
Wyss Institute for Biologically Inspired Engineering
Academic research institute
Lead institution on the gonorrhea study

A Harvard-affiliated institute that builds biologically inspired engineering tools, including the organ-on-a-chip used to test the compounds.
World Health Organization
World Health Organization
International public health agency
Classifies drug-resistant gonorrhea as a high-priority threat

The United Nations health agency that ranks drug-resistant pathogens and tracks gonorrhea resistance through its surveillance program.

Timeline

February 2020 June 2026

6 events Latest: June 29th, 2026 · 2 months ago
Tap a bar to jump to that date

  1. MP20 and A1 detailed in journal and Nature coverage

    Latest Publication

    Nature covers the Science Translational Medicine paper. MP20 disrupts the bacterial membrane and damages DNA; A1 blocks an enzyme needed to build the cell wall.

  2. Gonorrhea compounds reported

    Discovery

    Coverage details a graph neural network trained on about 38,650 molecules, then used to screen 6 million, yielding 83 active candidates and two leads.

  3. FDA approves zoliflodacin and gepotidacin for gonorrhea

    Regulatory

    The FDA approved zoliflodacin (Nuzolvence) and gepotidacin (Blujepa) on consecutive days—the first new oral gonorrhea treatments in nearly 40 years. A phase 3 trial showed zoliflodacin's single 3 g oral dose cured 91% of patients and matched the ceftriaxone-plus-azithromycin standard. Gepotidacin cured 93%.

  4. Generative models design compounds from scratch

    Method

    MIT researchers use generative AI to design new antibacterial structures atom by atom, rather than only ranking existing molecules.

  5. AI surfaces abaucin

    Discovery

    The lab reports abaucin, a narrow-spectrum compound against Acinetobacter baumannii, found by screening thousands of molecules with a trained model.

  6. Deep learning finds halicin

    Discovery

    Collins's group reports halicin, a compound found by a neural network, killing several drug-resistant bacteria in mice. It is the method's first proof.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

February 2020

Halicin discovery (2020)

Collins's team trained a neural network to predict antibacterial activity, then ran it across a drug-repurposing library. It flagged halicin, a molecule once studied for diabetes, which killed many drug-resistant strains in mice.

Then

The find drew wide attention as the first antibiotic surfaced by deep learning.

Now

It established the screen-and-confirm method the gonorrhea work now extends to a harder target.

Why this matters now

The gonorrhea study uses the same core idea, scaled from a small library to roughly 6 million compounds.

May 2023

Abaucin against Acinetobacter baumannii (2023)

The lab screened about 7,500 molecules with a trained model and found abaucin, a compound that hits one dangerous hospital pathogen while sparing others. Narrow targeting can slow resistance and protect helpful bacteria.

Then

Abaucin worked against the target in mice and lab tests.

Now

It showed AI screens could deliver precise, narrow-spectrum drugs, not just broad killers.

Why this matters now

MP20 and A1 follow the same narrow-targeting logic against a single high-priority pathogen.

2024

Zoliflodacin oral antibiotic trial (2024)

A late-stage trial showed zoliflodacin, a first-in-class oral drug, matched standard injectable treatment for uncomplicated gonorrhea. It was the first genuinely new gonorrhea antibiotic class to reach that stage in decades.

Then

Results supported regulatory review of a new oral option.

Now

It showed new mechanisms can still beat a pathogen that has defeated older drugs.

Why this matters now

It marks the slow, expensive path the AI-found compounds must travel to reach patients.

Sources

(10)
+4
Nature Science Translational Medicine Wyss Institute Open Access Government Medical Xpress CIDRAP FDA STAT News Medical Daily CIDRAP